section name header

Indications ⬇

REMS


Unlabeled Use:
  • Prevention of disease caused by Haemophilus influenzae type B in close contacts.
  • Synergy with other antimicrobial agents for S. aureus infections.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Tuberculosis

Asymptomatic Carriers of Meningococcus

H. influenzae Prophylaxis

Synergy for S. aureus Infections

US Brand Names ⬆ ⬇

, Rifadin, Rimactane

Action ⬆ ⬇

  • Inhibits RNA synthesis by blocking RNA transcription in susceptible organisms.
Therapeutic effects:
  • Bactericidal action against susceptible organisms.

Spectrum:

Classifications ⬆ ⬇

Therapeutic Classification: antituberculars

Pharmacologic Classification: rifamycins

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following oral administration.

Distribution: Widely distributed; enters CSF.

Protein Binding: 80%.

Metabolism/Excretion: Mostly metabolized by the liver; 60% eliminated in feces via biliary elimination.

Half-Life: 3 hr.

Canadian Brand Names ⬆ ⬇

Rofact

Time/Action Profile ⬆ ⬇

( plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid2–4 hr12–24 hr
IVrapidend of infusion12–24 hr

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

rif-AM-pin

Code ⬆

NDC Code